BOLT News and Press, Bolt Biotherapeutics Inc. From 08/12/25

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...

Bolt Biotherapeutics Inc. (BOLT) is expected to report $-6.4 for Q2 2025

2025-05-13 08:57:30 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biotherapeutics Read the full article on Seeking Alpha For...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity Bolt is running a partnering process to adva...

Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will h...

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWS...

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activ...

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 i...

2025-03-24 16:29:07 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biotherapeutics Read the full article on Seeking Alpha For...